Contrasting Carmell (NASDAQ:CTCX) & Modular Medical (NASDAQ:MODD)

Carmell (NASDAQ:CTCX) and Modular Medical (NASDAQ:MODD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of recent ratings for Carmell and Modular Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carmell	0	0	0	0	0.00
Modular Medical	0	0	1	0	3.00

Modular Medical has a consensus target price of $5.00, indicating a potential upside of 197.62%. Given Modular Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Modular Medical is more favorable than Carmell.

Risk & Volatility

Carmell has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Modular Medical has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Valuation & Earnings

This table compares Carmell and Modular Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carmell	$32,839.00	170.16	-$15.44 million	N/A	N/A
Modular Medical	N/A	N/A	-$17.47 million	($0.63)	-2.67

Carmell has higher revenue and earnings than Modular Medical.

Profitability

This table compares Carmell and Modular Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carmell	N/A	-217.50%	-50.22%
Modular Medical	N/A	-246.01%	-191.95%

Institutional and Insider Ownership

24.2% of Carmell shares are owned by institutional investors. Comparatively, 27.5% of Modular Medical shares are owned by institutional investors. 29.0% of Carmell shares are owned by insiders. Comparatively, 32.3% of Modular Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Modular Medical beats Carmell on 6 of the 10 factors compared between the two stocks.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

About Modular Medical

Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.